Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies.

[1]  M. Drazner,et al.  Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy , 2020, Circulation. Heart failure.

[2]  G. Sayer,et al.  United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis , 2020, Clinical transplantation.

[3]  M. Sweetser,et al.  Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis , 2019, Journal of Neurology.

[4]  R. Falk,et al.  Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) , 2019, Blood.

[5]  B. Meiser,et al.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  A. Dispenzieri,et al.  Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis , 2018, Transplantation.

[7]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[8]  M. Sweetser,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[9]  D. Eisenberg,et al.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition , 2018, Proceedings of the National Academy of Sciences.

[10]  H. Katus,et al.  Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  A. Dispenzieri,et al.  Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation , 2017, Progress in transplantation.

[12]  D. Judge,et al.  Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[13]  J. Lefaucheur,et al.  Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study , 2017, Journal of Neurology.

[14]  L. Amass,et al.  Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  C. Rapezzi,et al.  Outcomes of Heart Transplantation for Transthyretin-Related Amyloid Cardiomyopathy , 2016 .

[16]  R. Treister,et al.  Validation of the composite autonomic symptom scale 31 (COMPASS‐31) in patients with and without small fiber polyneuropathy , 2015, European journal of neurology.

[17]  M. Wheeler,et al.  Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  Josef Stehlik,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report--2013; focus theme: age. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  J. Mandrekar,et al.  COMPASS 31 – A Refined and Abbreviated Composite Autonomic Symptom Score (P03.019) , 2013, Neurology.

[20]  M. Benson.  Liver transplantation and transthyretin amyloidosis , 2013, Muscle & nerve.

[21]  P. Hawkins,et al.  Cardiac transplantation for amyloid heart disease: the United Kingdom experience. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  R. Falk,et al.  Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. , 1998, Transplantation.